News and Trends 28 Oct 2017 Biomaterials Take the Stage at Dutch Design Week The Dutch Design Week featured several biodesign projects that explore how the future will be shaped by the advance of biotechnology. Let’s have a look at some of them. Celebrated annually in Eindhoven, the Dutch Design Week has become a hotspot where designers share the latest trends and technologies. In the last few years, biodesign […] October 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Oct 2017 French Biotech Gets Together with L’Oréal to Clean up our Streets Carbios and L’Oréal have had enough of the plastics bags and packaging littering our streets and will form a consortium for the bio-recycling of plastic on an industrial scale. Today, you’ll struggle to walk along a street without seeing plastic bottles, bags, and wrappers dropped by the wayside… but thankfully, help is at hand. Carbios, […] October 27, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2017 The FDA Recruits British Organs-on-Chips to Speed Up Drug Development CN Bio Innovations and the FDA have entered a research collaboration to better predict drug safety in drug development by using human organs-on-chips. CN Bio Innovations, a spin-out from the University of Oxford, will be working with scientists from the FDA’s Centre for Drug Evaluation and Research with the aim of integrating organ-on-a-chip technology in the […] October 26, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2017 New and Improved CRISPR: More Precise Genome Editing Now Possible US Scientists have developed a new form of CRISPR, base editing, which can repair tiny genome segments, smaller than a single gene. Here at Labiotech, we focus on European biotech, but this was too big to miss: Researchers based at MIT and Harvard have described a new way of editing DNA and RNA — base […] October 26, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2017 Here’s a Flashy New Technique to Model Disease Although we have come very far in understanding cells and their functions, many undiscovered characteristics still keep us in the dark. Creating experiments that mimic the cell’s in vivo environments as closely as possible is one of the many challenges researchers face when working with cells in their labs. Micropatterning is a technique that addresses […] October 26, 2017 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 25 Oct 2017 Shire’s Hemophilia Gene Therapy Boosted by Orphan Drug Designation The FDA has granted orphan drug designation to Shire’s hemophilia A gene therapy, giving it the boost it needs to catch up with others in the field. Shire specializes in the development of drugs for rare diseases, including hemophilia A – a bleeding disorder caused by a lack of clotting factor VIII activity in the […] October 25, 2017 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 25 Oct 2017 British Researchers Develop Clever Nanoparticles to Kill Cancer Cells The University of Surrey has developed nanoparticles that heat up to kill cancer cells, but can then be controlled to protect healthy tissue. Research from the University of Surrey, published in Nanoscale, has been put forward as a new form of thermotherapy. Although it has been available for a long time, thermotherapy’s use is limited by […] October 25, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 25 Oct 2017 The UK Recommends the use of GSK’s €594,000 Gene Therapy Amidst uncertainty about the commercial future of expensive gene therapies, the UK’s NICE has declared GSK’s Strimvelis offers “value for money.” Approved by the EMA last year, Strimvelis is one of the most expensive drugs on the market. Although GSK is offering a money-back guarantee and payment through instalments, the price of the gene therapy, […] October 25, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2017 Update: GSK’s Shingles Vaccines Impresses FDA Panel who Push for its Approval Update (24/10/2017): Shingrix has been approved by the FDA and will cost $280 (€238) for the required two shots, which should be covered by most insurance plans. Originally published on 13/9/2017 An FDA panel voted 11-0 to support the approval of GSK’s new shingles vaccine based on “impressive” efficacy and safety results in a Phase III […] October 24, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2017 British Scientists Prove that it Takes Very Few Mutations to Cause Cancer Researchers in the UK have analyzed over 7,500 tumors and estimate that a very low number of mutations is needed for cancer to develop. Researchers coming out of the prestigious Sanger Institute in Cambridge, UK has estimated that as few as 1 to 10 mutations are required to cause cancer. The study, published in Cell, was […] October 24, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 24 Oct 2017 French Biotech‘s Bacterial Product is Ready to Enter the Anti-Aging Skincare Market Montpellier-based Deinove has developed a bacterial anti-aging skincare product, which has shown its safety and healing capacity in studies so far. Deinove specializes in high-value compounds from rare bacteria, in particular, the Deinococcus genus. It has announced that it will launch its first cosmetic product into the anti-aging skincare market in 2018, which is based on a […] October 24, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 23 Oct 2017 FDA Grants Belgian Crohn’s Disease Candidate Orphan Designation TiGenix’s candidate for a nasty Crohn’s disease complication received orphan drug designation after agreeing on a global Phase III trial. TiGenix exploits the anti-inflammatory properties of donor-derived stem cells to treat diseases. One of its candidates, Cx601, is targeted at a complication of Crohn’s disease – a nasty inflammatory condition affecting the intestine. Cx601 met efficacy and safety […] October 23, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email